Key result
Pargyline prevents diabetic cardiac autophagy and restores pro-survival AKT signaling by normalizing microRNA profiles.
Why the study?
It was unclear whether MAO activity can post-transcriptionally regulate cardiomyocyte function and survival in diabetes beyond direct mitochondrial effects.
Does pharmacological inhibition of monoamine oxidase with pargyline normalize cardiac miRNA/mRNA expression profiles, prevent aberrant autophagy, and restore IGF1R/PI3K/AKT pro-survival signaling in a mouse model of type 1 diabetic cardiomyopathy?
Does pharmacological inhibition of monoamine oxidase with pargyline normalize cardiac miRNA/mRNA expression profiles, prevent aberrant autophagy, and restore IGF1R/PI3K/AKT pro-survival signaling in a mouse model of type 1 diabetic cardiomyopathy?
This preclinical study demonstrates that monoamine oxidase activity drives diabetic cardiomyopathy not only via direct mitochondrial oxidative stress but also by post-transcriptionally upregulating specific miRNAs (miR-133a-3p, miR-193a-3p, miR-27a-3p) that suppress pro-survival IGF1R/PI3K/AKT signaling and promote pathological autophagy.
Pargyline shows benefit in diabetic mouse cardiomyopathy; hypothesis-generating for human translation.
Diabetes leads to cardiomyopathy and heart failure, the leading cause of death for diabetic patients. Monoamine oxidase (MAO) inhibition in diabetic cardiomyopathy prevents oxidative stress, mitochondrial and endoplasmic reticulum stress and the development of diastolic dysfunction. However, it is unclear whether, in addition to the direct effects exerted on the mitochondria, MAO activity is able to post-transcriptionally regulate cardiomyocyte function and survival in diabetes. To this aim, we performed gene and miRNA expression profiling in cardiac tissue from streptozotocin-treated mice (model of type 1 diabetes (T1D)), administered with either vehicle or MAOs inhibitor pargyline for 12 weeks. We found that inhibition of MAO activity in T1D hearts leads to profound transcriptomic changes, affecting autophagy and pro-survival pathways activation. MAO activity in T1D hearts increased miR-133a-3p, -193a-3p and -27a-3p expression. These miRNAs target insulin-like growth factor receptor 1 (Igf1r), growth factor receptor bound protein 10 and inositol polyphosphate 4 phosphatase type 1A, respectively, all components of the IGF1R/PI3K/AKT signaling pathway. Indeed, AKT activation was significantly downregulated in T1D hearts, whereas MAO inhibition restored the activation of this pro-survival pathway. The present study provides an important link between MAO activity, transcriptomic changes and activation of pro-survival signaling and autophagy in diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Cagnin et al. (2022) studied Type 1 diabetic cardiomyopathy (streptozotocin-induced mouse model). Pargyline (MAO inhibitor) vs. Vehicle was evaluated on Cardiac mRNA and miRNA expression profiles, autophagy (LC3B-II levels), and IGF1R/PI3K/AKT pro-survival pathway activation (p=≤0.05). Pargyline inhibition of monoamine oxidase in type 1 diabetic mice prevented aberrant cardiac autophagy and restored pro-survival IGF1R/PI3K/AKT signaling by normalizing miR-133a-3p, miR-193a-3p, and miR-27a-3p expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: